Insights in Treating Anxiety and the Pharmaceutical Perspective

Freda Lewis-Hall, MD, a clinician with extensive experience in practice and pharmaceutical development surveyed the persistent unmet need in anxiety and depression treatment. We spoke with Lewis-Hall to learn more about the pipeline of novel serotonergic agonists, particularly HLP-004 for generalized anxiety disorder and HLP003 for major depressive disorder, which recently showed positive results.^1,2 HLP-004 is an investigational intramuscular deuterated serotoninergic agonist, being developed for treatment resisted anxiety.²